PL EN
REVIEW PAPER
Epiretinal Membrane – What does It Change in Anti-vascular Endothelial Growth Factor Therapy Injection (anti-VEGF)?
 
More details
Hide details
1
Department of Ophthalmology, Medical University of Gdańsk, Poland Head: Professor Katarzyna Michalska-Małecka, PhD, MD
 
 
A - Research concept and design; B - Collection and/or assembly of data; C - Data analysis and interpretation; D - Writing the article; E - Critical revision of the article; F - Final approval of article
 
 
Submission date: 2025-12-04
 
 
Acceptance date: 2025-12-05
 
 
Publication date: 2026-01-15
 
 
Corresponding author
Paulina Glasner   

Katedra, Klinika Okulistyki Gdańskiego Uniwersytetu Medycznego, ul. Smoluchowskiego 17, 80-210, Gdańsk, Poland
 
 
Ophthalmology 2025;28(3):15-23
 
KEYWORDS
TOPICS
ABSTRACT
Epiretinal membrane is a type of fibrous proliferation on the retinal surface in the macular region. Its most common symptoms include metamorphopsia, micropsia, macropsia, and reduced visual acuity. When these symptoms are present, patients are typically treated surgically with posterior vitrectomy. During the procedure, both the epiretinal membrane and the internal limiting membrane are removed. Postoperatively, an improvement in visual acuity and resolution of membrane-related symptoms are generally observed. A particular clinical challenge arises when epiretinal membrane coexists with diabetic macular edema or exudative age-related macular degeneration. In such cases, the membrane is believed to reduce the effectiveness of anti-vascular endothelial growth factor therapy. When these conditions coexist, surgical treatment may also be applied; however, outcomes are not always satisfactory. It is generally assumed that surgery should be performed at least after a loading phase of pharmacological therapy and, optimally, after a longer period if therapeutic effects remain insufficient. This paper reviews the available literature and presents clinical cases of patients treated with both surgical intervention and anti-vascular endothelial growth factor therapy.
REFERENCES (9)
1.
Kanukollu VM, Agarwal P: Epiretinal Membrane. [Updated 2023 Jul 24]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/b....
 
2.
Fraser-Bell S, Guzowski M, Rochtchina E, et al.: Five-year cumulative incidence and progression of epiretinal membranes: the Blue Mountains Eye Study. Ophthalmology. 2003 Jan; 110(1): 34– 40. [PubMed].
 
3.
Namba R, Kaneko H, Suzumura A, et al.: In Vitro Epiretinal Membrane Model and Antibody Permeability: Relationship With Anti-VEGF Resistance in Diabetic Macular Edema. Invest Ophthalmol Vis Sci. 2019 Jul 1; 60(8): 2942– 2949. doi: 10.1167/iovs.19-26788. PMID: 31284311.
 
4.
Lee SJ, Koh HJ: Effects of vitreomacular adhesion on anti- vascular endothelial growth factor treatment for exudative age-related macular degeneration. Ophthalmology. 2011; 118: 101–110.
 
5.
Christoforidis JB, Xie Z, Jiang A, et al.: Serum levels of intravitreal bevacizumab after vitrectomy, lensectomy and non-surgical controls. Curr Eye Res. 2013; 38: 761–766.
 
6.
Schechet SA, Devience E, Thompson JT: The effect of internal limiting membrane peeling on idiopathic epiretinal membrane surgery, with a review of the literature. Retina. 2017; 37(5): 87380. https://doi.org/10.1097/IAE.00....
 
7.
Mojana F, Cheng L, Bartsch DU, et al.: The role of abnormal vitreomacular adhesion in age-related macular degeneration: spectral optical coherence tomography and surgical results. Am J Ophthalmol. 2008; 146: 218–227.
 
8.
Lee SJ, Koh HJ: Effects of vitreomacular adhesion on anti-vascular endothelial growth factor treatment for exudative age-related macular degeneration. Ophthalmology. 2011; 118: 101–110.
 
9.
Kimura S, Morizane Y, Toshima S, et al.: Efficacy of vitrectomy and inner limiting membrane peeling in age-related macular degeneration resistant to anti-vascular endothelial growth factor therapy, with vitreomacular traction or epiretinal membrane. Graefes Arch Clin Exp Ophthalmol. 2016; 254: 1731–1736.
 
eISSN:1689-362X
ISSN:1505-2753
Journals System - logo
Scroll to top